Related Experiment Video
Updated: Jul 3, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Pharmacogenetics in solid organ transplantation: current status and future directions
Hylke de Jonge1, Dirk R J Kuypers
1Department of Nephrology and Renal Transplantation, University Hospitals Leuven, B-3000 Leuven, Belgium.
Transplantation Reviews (Orlando, Fla.)
|July 18, 2008
Summary
Pharmacogenetics offers potential for personalized immunosuppressive drug therapy in organ transplantation. Further research is needed to determine if genetic profiling can become a routine clinical tool for optimizing treatment and reducing side effects.
Area of Science:
- Pharmacogenomics and Transplantation Medicine
Background:
- Individualized immunosuppressive drug therapy is crucial for optimizing efficacy and minimizing toxicity in solid organ transplantation.
- Genetic variations influence how patients process and respond to immunosuppressants, presenting an opportunity for personalized medicine.
Purpose of the Study:
- To review the current state of pharmacogenetic and pharmacogenomic research in tailoring immunosuppressive drug therapy.
- To assess the potential of using genetic polymorphisms to guide immunosuppressive regimens in transplant recipients.
Main Methods:
- Review of studies investigating the impact of single nucleotide polymorphisms (SNPs) in genes related to drug metabolism, transport, and targets.
- Analysis of pharmacogenetic data for immunosuppressive drugs including tacrolimus, cyclosporine, sirolimus, mycophenolic acid, and corticosteroids.
Main Results:
- Numerous studies have explored the influence of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of key immunosuppressants.
- Evidence suggests a link between specific genetic profiles and patient response to immunosuppressive therapy, though variability exists.
Conclusions:
- Pharmacogenetic research holds promise for individualizing immunosuppressive therapy in solid organ transplantation.
- The clinical utility of pharmacogenetic profiling for routine immunosuppressive drug management is still under investigation and requires further validation.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...